Systagenix Product Launch

Oct 26, 2009

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

RNS Number : 3314B
Advanced Medical Solutions Grp PLC
26 October 2009

For Immediate Release   

26 October 2009

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

Launch of new silver alginate dressing

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, today announces 

that Systagenix Wound Management (“Systagenix”), the exclusive  marketing and distribution partner for the Groups fibre-based silver alginate technology, has expanded its SILVERCEL* anti-microbial wound dressings offering with the introduction of SILVERCEL* Non-Adherent Hydro-Alginate Dressing.  The new product has recently been launched in the US with introduction intEurope and other international markets during October.

Silver is widely recognised as a safe and effective broad-spectrum anti-microbial agent for infection control. In 2003, 

AMS developed a range of wound dressings whereby silver fibres were incorporated into its proprietry calcium alginate technology which allows a controlled and sustained release of silver into the wound without compromising the performance of the base alginate – a natural wound dressing derived from seaweed.  Following regulatory approvals, these products were launched under the SILVERCEL* brand and are sold by Systagenix in all the key advanced woundcare markets worldwide. The global silver alginate market is currently estimated at around $350 million and growing at 15% per annum.

The new product announced today, SILVERCEL* Non-Adherent, is a dressing with the unique benefit of a perforated film on both sides of the existing SILVERCEL* dressing. Suitable for use on moderately to heavily exuding infected wounds and effective against a broad range of micro-organisms, it is specifically designed for easy removal thus minimising the trauma associated with dressing changes.

UK based Systagenix has clear objectives to build on 75 years of history at the forefront of pioneering and innovative woundcare to become the world’s strongest and most admired woundcare company. It currently supplies over 30 million wound dressings a month to treat patients in hospitals, nursing homes and in their own homes in over 100 countries.

Commenting on this announcement, Dr. Don Evans, Chief Executive Officer of Advanced Medical Solutions, said:

With their strong global presence and commitment to inventive products for chronic and acute wound management, Systagenix is an ideal partner for the marketing and distribution of our fibre-based silver alginate technology. The introduction of this latest product innovation is another key milestone for AMS in exploiting the dynamic silver alginate market and launching novel woundcare products with major global players.”

For further information, please contact:

Advanced Medical Solutions Group plc

Don Evans, Chief Executive Officer

Mary Tavener, Finance Director

  Tel: +44 (0) 1606 545508

Buchanan Communications

Mark Court / Stasa Filiplic

Tel: +44 (0) 20 7466 5000

Investec Bank plc

Tel: +44 (0) 20 7597 5970

Tim Pratelli / Daniel Adams

Notes to Editors:

Advanced Medical Solutions develops and manufactures products for the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative products for advanced woundcare and wound closure.  

The advanced woundcare products are based on the moist wound healing principle. AMS uses its inhouse technology to provide a vertically integrated ‘one stop shop’ for all categories of moist wound healing products. The Company has the capability to move a product from design and development through to production and delivery for distribution and sale into customer markets.

AMS’ technology in cyanoacrylate based tissue adhesives is used for the closure of small cuts and trauma wounds through to large surgical incisions, and also for protecting or sealing skin to prevent breakdown or infection. 

AMS’ products which currently serve the majority of the key global markets are sold either direct or through strategic partners and distributors. 

Systagenix Wound Management

Systagenix Wound Management was formed in December 2008 following the management buyout of Johnson & Johnson’s professional wound care business, which had a 75-year heritage.

Systagenix, with its head office based in GatwickUK, employs more than 800 people globally. It develops, manufactures and distributes a wide range of unique and advanced wound care products to more than 100 countries worldwide.

With products designed to heal some of the most challenging acute and chronic wounds, Systagenix offers products within various wound care categories, including moist wound healing, antimicrobial and active healing.

This information is provided by RNS
The company news service from the London Stock Exchange




For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.